Does Mounjaro wear off during the week — and what that means for you

Step 1: understanding the rise and fall after each injection

Every weekly Mounjaro injection produces a concentration curve in your bloodstream. Levels peak within around 24 to 72 hours of the injection, then begin to decline as your body clears the medicine. The five-day half-life means that by day seven, roughly half the peak concentration from that dose remains, but the trough is real and measurable.

That gradual decline is what most people interpret as the medicine "wearing off". In practical terms: the appetite suppression that felt solid on Tuesday can feel noticeably lighter by Sunday. Some people also notice that nausea, if they experienced it near injection day, has faded, which is often a relief, even if it arrives alongside the return of some hunger. Both are the same pharmacology at work.

The NHS medicines page on tirzepatide describes once-weekly dosing as the licensed schedule and notes that the prescriber manages any changes to it, so the rhythm is not something to tinker with unilaterally. A useful checking habit: note your injection day in your phone calendar, then jot a single word about your appetite each morning for a week. That one-minute log gives a prescriber something concrete to work with at your next review.

Step 2: why the pattern usually settles once you reach steady state

With any medicine that accumulates over repeated doses, the first few weeks look different from week eight. During the first month of weekly Mounjaro injections, each dose is adding to a base that has not yet plateaued. Once steady state is reached (typically after four to six weeks of consistent weekly dosing) the troughs between injections are higher than they were at the start, because some drug from previous weeks is still present when the new dose arrives.

In plain English: the "running low" feeling that some people notice acutely in week two or three often settles down by week six or eight, as the accumulation fills in the gaps. This is one reason prescribers ask patients to give each new dose level enough time before concluding it is not working. The tirzepatide overview on our site covers the titration schedule in more detail.

Steady state does not eliminate the curve, but it raises the floor. People who still experience pronounced end-of-week hunger after two months on a stable dose are describing something worth raising at their next clinical review, not ignoring.

Step 3: what dose level has to do with it

The 2.5mg starting dose is a tolerability step. Its purpose is to let your system adjust to the medicine, not to deliver the full appetite effect. At 2.5mg, the end-of-week dip can feel sharper simply because the overall drug exposure is lower. As the prescriber titrates upward through 5mg, 7.5mg and beyond, most people find the weekly variation in appetite control becomes less pronounced.

This is part of why the titration schedule exists. It is not purely about tolerating side effects; it is about building toward a dose where the therapeutic benefit is consistent across the whole week, not just the first few days. For context on how UK pricing and dose levels interact, the Eli Lilly UK price increase page sets out the background on the current market.

If you are on a higher dose and still noticing a significant dip by day six, that is a legitimate clinical data point, the kind of thing a prescriber weighs when deciding whether to adjust anything. The NICE appraisal of tirzepatide (NICE TA1026) describes the treatment as subject to ongoing clinical review, which is exactly why regular check-ins are built into the process. Our Mounjaro page has a broader overview of how the licensed schedule works in practice.

Step 4: when end-of-week wear-off becomes a clinical question

There is a difference between a normal, mild softening of appetite suppression toward day seven and a pronounced return of hunger, cravings or food preoccupation that makes the end of the week genuinely difficult. The first is pharmacology doing exactly what it should. The second is worth documenting and discussing.

Signs that wear-off has crossed into clinical territory include: feeling like the medicine has no effect at all by day five or six, significant emotional difficulty around food in the days before your next injection, or physical symptoms that follow a regular weekly pattern. None of these means Mounjaro is wrong for you; they are data points a prescriber uses to review dose, titration pace, or injection timing.

Mood and appetite are closely linked, and some patients describe low mood or irritability in the days before injection. If that resonates, it is worth raising honestly. Our page on Mounjaro and mood covers what is known about psychological side effects. The NHS tirzepatide patient information page also lists what to report and when to seek help. For more on the week-by-week experience specifically, this page looks at end-of-week patterns in detail, and when Mounjaro wears off covers the timing question from a different angle. If you are weighing whether your current dose is right, checking your eligibility with our prescribers is a sensible next step.